source
- Pfizer targets Europe first for upcoming Lyme disease vaccine amid rising US casesPfizer is planning to launch its Lyme disease vaccine in Europe first, leveraging its existing tick-borne encephalitis franchise in the region. The vaccine, developed with French partner Valneva,…
- AbbVie licenses Nxera's EP4 gut-targeting IBD program for up to $1.47 billionAbbVie announced a licensing agreement with Nxera Pharma to acquire rights to its EP4 receptor agonist program aimed at inflammatory bowel disease. The deal includes an upfront payment of $100 mil…